A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept

Health Technol Assess. 2002;6(17):1-43. doi: 10.3310/hta6170.
No abstract available

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adolescent
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / economics*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Juvenile / drug therapy*
  • Arthritis, Juvenile / epidemiology
  • Arthritis, Juvenile / pathology
  • Child
  • Child, Preschool
  • Cost of Illness
  • Drug Costs
  • Etanercept
  • Evidence-Based Medicine
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / economics*
  • Immunoglobulin G / therapeutic use*
  • Quality-Adjusted Life Years
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • State Medicine
  • Treatment Outcome
  • United Kingdom

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept